Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019. It is grouped under the following drug class(es): Schedule V controlled substances. Its therapeutic use is listed as anti-epileptic drugs, anticonvulsants and central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Xcopri and Cenobamato. It is listed as a controlled drug substance (Schedule V). Its PubChem CID is 11962412.
Cenobamate
| CAS No | 913088-80-9 |
|---|---|
| Molecular Formula | C10H10ClN5O2 |
| Molecular Weight | 267.67 g/mol |
| Synonyms | [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels.
The listed CAS number is 913088-80-9.
The listed molecular formula is C10H10ClN5O2.
The listed molecular weight is 267.67 g/mol.
[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate.
The source lists Xcopri and Cenobamato.